ALCESTER, United Kingdom, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology innovation company, today announces that management will be participating in three upcoming investor conferences.

Original post:
Quanta to Participate in Upcoming Virtual Investor Conferences

- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million  - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for childhood-onset growth hormone deficiency expected to be initiated in Q1 2021

Read this article:
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end –

Read the rest here:
Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus

Continue reading here:
Vaxart Hosting Key Opinion Leader Panel Call for Investors

Granted methods patent for Versamune® platform by the United States Patent and Trademark Office Granted methods patent for Versamune® platform by the United States Patent and Trademark Office

View original post here:
PDS Biotech Announces New and Broad Versamune® Platform Patent Claims

First patients on track for enrollment this year

Here is the original post:
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and...

MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), will host an Analyst and Investor Event on Tuesday, December 8, 2020, from 9:00 a.m. to approximately 11:30 a.m. EST.

Link:
Syneos Health to Host Virtual Analyst and Investor Event on December 8, 2020

? Early & High Uric Acid dose dependent association in Acute Kidney Injury from COVID-19 ? ? Early & High Uric Acid dose dependent association in Acute Kidney Injury from COVID-19 ?

See the rest here:
XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

WAKEFIELD, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that an overseas Clinical Trial Application (CTA) has been submitted to the governing health agency, with a U.S. Investigational New Drug (IND) application also to be submitted this week to the FDA. Both these submissions are part of final preparations for the Company’s multinational Phase 2 clinical trial of Brilacidin for COVID-19, which is on track to commence in 2020 upon gaining required approvals.

View original post here:
Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study

BRISBANE, Calif. and ST. LOUIS, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Ronald Krasnow, Esq. as Chief Operating Officer. In this newly created position, Mr. Krasnow will report to Julie Hambleton, M.D., Arch Oncology’s Interim President and Chief Executive Officer.

Read the original post:
Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer

BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020.

See the rest here:
Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium

WILLIAMSVILLE, N.Y., Nov. 16, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company will present and meet with investors at the Virtual Fall Investor Summit. The conference is being held virtually November 16 -18, 2020.

See original here:
22nd Century Group to Present at the Virtual Fall Investor Summit on November 17

PETALUMA, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spectrum Antimicrobials, Inc., a subsidiary of Collidion, Inc. announces the development of a novel antiviral drug candidate designed to treat pulmonary infections. SPC-069 is a new class of therapy designed to treat viral, bacterial, and fungal infections in the lung and respiratory tract. This promising therapy was developed to eradicate not only common pathogens but also those caused by antibiotic resistant strains known as “Super Bugs.” The Company plans to advance this drug candidate into human clinical studies as soon as possible with a partner or upon completion of its financing.

Originally posted here:
Spectrum Antimicrobials, Inc. Announces Breakthrough Drug Candidate for Prevention and Treatment of Pulmonary Infections

Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer

Link:
TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and...

HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.

Link:
Nymox Provides Update on Regulatory Filing Activities

SUNNYVALE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Simplify Medical, Inc., maker of the Simplify® Cervical Artificial Disc, announced today that David Hovda, President and Chief Executive Officer, will present at the 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum and invites investors to participate via the conference webcast. Please see additional details below:

Follow this link:
Simplify Medical to Present at the 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum

Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia

See more here:
Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition Study

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin presented in an oral presentation given today by Lindsay T. Fourman, M.D., of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).

See the rest here:
Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASH

.biz has announced a business intelligence study on Global Autologous Stem Cell Based Therapies Market 2020 by Company, Type and Application, Forecast to 2025 that reveals diverse information allowing keen market participants to understand the measures of the market. The report sheds light on market developments, noteworthy trends as well as competitive vendor activities and performance analysis. The report is aimed at offering readers real-time data vital to drive future-ready investment decisions. The research focuses on the dominant trends, persistent challenges, and threats, as well as budding opportunities influencing growth scenarios in the global Autologous Stem Cell Based Therapies market. The market report is a comprehensive research that demonstrates overall consumption structure, development trends, well-known providers, and market segments.

Executive Summary:

The report assesses the historical and future timelines, accurate growth predictions, and forecast estimations, and fast-changing market forces. The report draws references for an extensive analysis of the global Autologous Stem Cell Based Therapies market, entailing important details about key market players, with a broad overview of expansion probability and expansion strategies. The report has been designed and presented in the form of tables and figures and other statistical to generate higher reader perception. Later in the report, details on manufacturer information, leading market participants as well as other key players have also been added.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/67562

Understanding Scope:

Leading companies covered in the report include: Regeneus, US STEM CELL, INC., Mesoblast, Med cell Europe, Pluristem Therapeutics Inc, Tigenix, Brainstorm Cell Therapeutics

By the product type, the market is primarily split into: Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells

By the end-users/application, this report covers the following segments: Neurodegenerative Disorders, Autoimmune Diseases, Cardiovascular Diseases

The report contains detailed market size and forecast for the following countries and regions: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/67562/global-autologous-stem-cell-based-therapies-market-2020-by-company-type-and-application-forecast-to-2025

Moreover, upstream raw materials, downstream demand analysis, and end-user industry listings have been studied with vendors in this global Autologous Stem Cell Based Therapies market. Product flows and distribution channels were also presented in this research report. The report includes broad market segmentation based on the different product types, a wide application spectrum, the key regions, and the existing competition among players. In addition, the report reviews pricing analysis, profit margins, cost and demand volatility, import/export dynamics, gross revenue, and various other aspects of the market.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

View original post here:
Global Autologous Stem Cell Based Therapies Market 2020 Segmentation, Statistics, Top Manufacturers, Regional Analysis and Forecast to 2025 - The...

DUBLIN--(BUSINESS WIRE)--The "Cell Therapy and Gene Therapy Markets" report has been added to ResearchAndMarkets.com's offering.

This is an exciting and interesting time in the cell and gene therapy industry. The science is moving ahead as industry industrializes and standardizes the manufacturing and commercialization of products. Cell and gene therapy products are transforming the treatment of cancers and genetic diseases, as well as expanding into other areas of medicine including autoimmune diseases, cardiovascular diseases, musculoskeletal disease, dermatological diseases, and many others.

Cell Therapy and Gene Therapy Markets presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.

The following conditions/disorders are covered:

Dermatology, including:

Oncology, including:

Ophthalmic Conditions, including:

Other Conditions, including:

The report comments on the current COVID-19 cell and gene therapy pipeline. There are a number of companies that are responding to the call to develop a therapeutic or vaccine for the coronavirus, including:

The leading influencers in the market are those which have become first-to-market participants in the cell and gene therapy segment, have new developments which may disrupt current market conditions, and/or have an extensive pipeline sure to impact the market in the long-term forecast:

Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2019 and the expected market for 2020 based on first-quarter company reports and are expressed in current dollars. Forecasts are provided through 2025 and an extended forecast for 2030. The size of each market segment refers to manufacturers' revenues.

For more information about this report visit https://www.researchandmarkets.com/r/ek1qqb

More:
Cell Therapy and Gene Therapy Markets, 2019-2020 & Forecast to 2025 and 2030 - ResearchAndMarkets.com - Business Wire